Clinical Trial Update: Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial investigates golcadomide in combination with rituximab as bridging therapy for relapsed or refractory aggressive B-cell non-Hodgkin lym…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aggressive B-cell Non-hodgkin Lymphoma
• Cutaneous Diffuse Large B-cell Lymphoma Leg Type
• Diffuse Large B-cell Lymphoma
• Diffuse Large B-cell Lymphoma Associated with Chronic Inflammation
• Ebv-positive Diffuse Large B-cell Lymphoma
• Intravascular Large B-cell Lymphoma
• Mediastinal Large B-cell Lymphoma
• Transformed Non-hodgkin Lymphoma

Drugs mentioned

• Golcadomide (golcadomide)
• Rituximab (rituximab)

Snippet

Sponsor: Mayo Clinic | Conditions: Large B-Cell Lymphoma With IRF4 Rearrangement, Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma | Phase 2 | Status: RECRUITING